<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin E for Alzheimer's dementia and mild cognitive impairment - Farina, N - 2017 | Cochrane Library</title> <meta content="Vitamin E for Alzheimer's dementia and mild cognitive impairment - Farina, N - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin E for Alzheimer's dementia and mild cognitive impairment - Farina, N - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002854.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin E for Alzheimer's dementia and mild cognitive impairment" name="citation_title"/> <meta content="Nicolas Farina" name="citation_author"/> <meta content="Brighton and Sussex Medical School" name="citation_author_institution"/> <meta content="n.farina@bsms.ac.uk" name="citation_author_email"/> <meta content="David Llewellyn" name="citation_author"/> <meta content="University of Exeter" name="citation_author_institution"/> <meta content="Mokhtar Gad El Kareem Nasr Isaac" name="citation_author"/> <meta content="Sussex Partnership NHS Foundation Trust" name="citation_author_institution"/> <meta content="Naji Tabet" name="citation_author"/> <meta content="Brighton and Sussex Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD002854.pub5" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Alzheimer Disease [*drug therapy, mortality]; Antioxidants [adverse effects, *therapeutic use]; Cognition [drug effects]; Cognitive Dysfunction [*drug therapy, mortality]; Disease Progression; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Vitamin E [adverse effects, *therapeutic use]; alpha‐Tocopherol [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002854.pub5&amp;doi=10.1002/14651858.CD002854.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002854\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002854\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","ja","fr","pl","hr","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002854.pub5",title:"Vitamin E for Alzheimer\u0027s dementia and mild cognitive impairment",firstPublishedDate:"Apr 18, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002854.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002854.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002854.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002854.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002854.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002854.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002854.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002854.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002854.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002854.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10674 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002854.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0113"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/appendices#CD002854-sec-0118"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/table_n/CD002854StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/table_n/CD002854StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin E for Alzheimer's dementia and mild cognitive impairment</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#CD002854-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nicolas Farina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#CD002854-cr-0003">David Llewellyn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#CD002854-cr-0004">Mokhtar Gad El Kareem Nasr Isaac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information#CD002854-cr-0005">Naji Tabet</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information/en#CD002854-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002854.pub5">https://doi.org/10.1002/14651858.CD002854.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002854-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002854-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002854-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002854-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002854-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002854-abs-0001" lang="en"> <section id="CD002854-sec-0001"> <h3 class="title" id="CD002854-sec-0001">Background</h3> <p>Vitamin E occurs naturally in the diet. It has several biological activities, including functioning as an antioxidant to scavenge toxic free radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has led to interest in the use of vitamin E supplements to treat mild cognitive impairment (MCI) and Alzheimer's disease (AD). This is an update of a Cochrane Review first published in 2000, and previously updated in 2006 and 2012. </p> </section> <section id="CD002854-sec-0002"> <h3 class="title" id="CD002854-sec-0002">Objectives</h3> <p>To assess the efficacy of vitamin E in the treatment of MCI and dementia due to AD.</p> </section> <section id="CD002854-sec-0003"> <h3 class="title" id="CD002854-sec-0003">Search methods</h3> <p>We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources on 22 April 2016 using the terms: "Vitamin E", vitamin‐E, alpha‐tocopherol. </p> </section> <section id="CD002854-sec-0004"> <h3 class="title" id="CD002854-sec-0004">Selection criteria</h3> <p>We included all double‐blind, randomised trials in which treatment with any dose of vitamin E was compared with placebo in people with AD or MCI. </p> </section> <section id="CD002854-sec-0005"> <h3 class="title" id="CD002854-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We rated the quality of the evidence using the GRADE approach. Where appropriate we attempted to contact authors to obtain missing information. </p> </section> <section id="CD002854-sec-0006"> <h3 class="title" id="CD002854-sec-0006">Main results</h3> <p>Four trials met the inclusion criteria, but we could only extract outcome data in accordance with our protocol from two trials, one in an AD population (n = 304) and one in an MCI population (n = 516). Both trials had an overall low to unclear risk of bias. It was not possible to pool data across studies owing to a lack of comparable outcome measures. </p> <p>In people with AD, we found no evidence of any clinically important effect of vitamin E on cognition, measured with change from baseline in the Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) over six to 48 months (mean difference (MD) ‐1.81, 95% confidence interval (CI) ‐3.75 to 0.13, P = 0.07, 1 study, n = 272; moderate quality evidence). There was no evidence of a difference between vitamin E and placebo groups in the risk of experiencing at least one serious adverse event over six to 48 months (risk ratio (RR) 0.86, 95% CI 0.71 to 1.05, P = 0.13, 1 study, n = 304; moderate quality evidence), or in the risk of death (RR 0.84, 95% CI 0.52 to 1.34, P = 0.46, 1 study, n = 304; moderate quality evidence). People with AD receiving vitamin E showed less functional decline on the Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory than people receiving placebo at six to 48 months (mean difference (MD) 3.15, 95% CI 0.07 to 6.23, P = 0.04, 1 study, n = 280; moderate quality evidence). There was no evidence of any clinically important effect on neuropsychiatric symptoms measured with the Neuropsychiatric Inventory (MD ‐1.47, 95% CI ‐4.26 to 1.32, P = 0.30, 1 study, n = 280; moderate quality evidence). </p> <p>We found no evidence that vitamin E affected the probability of progression from MCI to probable dementia due to AD over 36 months (RR 1.03, 95% CI 0.79 to 1.35, P = 0.81, 1 study, n = 516; moderate quality evidence). Five deaths occurred in each of the vitamin E and placebo groups over the 36 months (RR 1.01, 95% CI 0.30 to 3.44, P = 0.99, 1 study, n = 516; moderate quality evidence). We were unable to extract data in accordance with the review protocol for other outcomes. However, the study authors found no evidence that vitamin E differed from placebo in its effect on cognitive function, global severity or activities of daily living . There was also no evidence of a difference between groups in the more commonly reported adverse events. </p> </section> <section id="CD002854-sec-0007"> <h3 class="title" id="CD002854-sec-0007">Authors' conclusions</h3> <p>We found no evidence that the alpha‐tocopherol form of vitamin E given to people with MCI prevents progression to dementia, or that it improves cognitive function in people with MCI or dementia due to AD. However, there is moderate quality evidence from a single study that it may slow functional decline in AD. Vitamin E was not associated with an increased risk of serious adverse events or mortality in the trials in this review. These conclusions have changed since the previous update, however they are still based on small numbers of trials and participants and further research is quite likely to affect the results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002854-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002854-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002854-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002854-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002854-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002854-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002854-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002854-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002854-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002854-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002854-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002854-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002854-abs-0004" lang="en"> <h3>The use of vitamin E in the treatment of mild cognitive impairment and Alzheimer's disease (AD) </h3> <p><b>Background</b> </p> <p>Vitamin E is found in a variety of foods, including vegetable oils and fats, nuts and seeds. Some animal and non‐interventional studies have suggested it might have a role in the prevention or treatment of Alzheimer's disease (AD). However, evidence has linked vitamin E with potentially serious side effects and even an increased risk of death. In this review, we looked for evidence about the effect of vitamin E on people who had either dementia due to AD or milder problems with memory or thinking (mild cognitive impairment or MCI). People with MCI have an increased risk of developing dementia. </p> <p><b>Included trials</b> </p> <p>We searched for clinical trials published up to April 2016 which had randomly allocated people with dementia due to AD or with MCI to treatment with vitamin E supplements or a placebo (pretend treatment). We found three trials that investigated the effects of vitamin E on people with AD, but we could extract data from only one of these trials (304 participants). We found only one trial with 516 participants which investigated the effects of vitamin E on people with MCI. The quality of these two trials was generally good. </p> <p><b>Results</b> </p> <p>Vitamin E did not reduce the number of people with MCI who developed dementia over three years. We also found no evidence that vitamin E improved cognition (e.g. learning and memory) in people with MCI or with dementia due to AD. One trial found that people with dementia due to AD who took vitamin E could manage daily activities (e.g. bathing and dressing) better than people who took placebo. There was no evidence from these trials that vitamin E caused significant harm to participants, but these types of trials are not the best way to look for harmful effects unless the effects are very common. Because all the results came from single trials, it is likely that further research could lead to different conclusions. </p> <p><b>Conclusion</b> </p> <p>From limited evidence, we found nothing to suggest that there are either benefits or harms from vitamin E supplements. As the quality of evidence was only moderate, further trials are needed to confirm the findings. It is possible that different types or doses of vitamin E might have different effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002854-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002854-sec-0113"></div> <h3 class="title" id="CD002854-sec-0114">Implications for practice</h3> <section id="CD002854-sec-0114"> <p>This review found little evidence for the efficacy of vitamin E (alpha‐tocopherol) in the treatment of Alzheimer's disease (AD). We found no evidence that it affects cognition, although there was moderate quality evidence from one study that it may slow functional decline, changing our conclusions from the previous update. However, based upon the quality of evidence, it is likely that further trials could have an impact on this finding. We consider it important to inform patients, carers and professionals about the lack of evidence for efficacy and the potential hazards of using vitamin E in AD. It should be noted that the conclusions are based only on the alpha‐tocopherol formulation of vitamin E, and hence no comment can be made on the efficacy of other preparations. </p> </section> <h3 class="title" id="CD002854-sec-0115">Implications for research</h3> <section id="CD002854-sec-0115"> <p>Vitamin E is a powerful antioxidant and plays an important role in protecting cells against the harmful effects of free radicals. There is sufficient evidence from laboratory and animal studies to consider it of potential interest as a treatment for people with AD. Overall, however, there continues to be a paucity of randomised controlled trials investigating the efficacy of vitamin E in AD. The findings from <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> are interesting and indicate that vitamin E may slow functional decline in AD. Further research is now warranted to assess this further. Additional research is also needed to explore the effects of vitamin E treatment on other clinically relevant outcomes, such as quality of life, which was not assessed in any of the trials identified in this review. This review is a good example of the need to have more uniform outcomes across trials, with a focus on identifying outcomes that are meaningful to patients and carers. <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> was a small study, but interesting as it showed a harmful effect on cognition in those participants whose oxidative stress markers did not respond to vitamin E intake. However, the size and high number of dropouts in this study limits the conclusions that can be drawn. Other studies included in this review did not measure antioxidant or nutritional levels prior to randomisation. The assessment of oxidative stress markers in future trials should be considered in order to understand further the oxidant‐antioxidant balance in relation to vitamin E effects in AD. In addition, the exclusive use of the alpha‐tocopherol form of vitamin E in clinical trials has been criticised. Future studies should investigate other tocopherol and tocotrienol forms. We will consider investigating subgroups by vitamin E formulation and oxidative stress response in future updates of this review. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002854-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002854-sec-0029"></div> <div class="table" id="CD002854-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> multicentre, US </p> <p><b>Intervention:</b> vitamin E (capsules 2000 IU/day in 2 divided doses) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin E (capsules 2000 IU/day in 2 divided doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> <br/> LS mean change from baseline using the ADAS‐Cog </p> <p>Scale from: 0 to 70</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in cognitive function in placebo group was <b>7.78</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in cognitive function in the intervention group was <b>1.81 lower</b> <br/> (3.75 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores represent worse cognitive function.</p> <p>A 4‐point difference in ADAS‐cog has been considered the MCID.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Number of participants reporting ≥ 1 serious adverse event</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> <br/> (444 to 656) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.71 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> <p>Number of deaths</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (106 to 273) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/> (0.52 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> <br/> LS mean change from baseline using the ADCS‐ADL </p> <p>Scale from: 0 to 78</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in activities of daily living in the placebo group was <b>‐16.96</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in activities of daily living in the intervention group was <b>3.15 higher</b> <br/> (0.07 to 6.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores represent better activities of daily living.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer Disease Assessment Scale ‐ Cognitive Subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory;<b>CI:</b> confidence interval; <b>LS:</b> least square; <b>MCID:</b> minimum clinically important difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due to imprecision. Evidence from a single study of modest size. This is supported by dichotomous data not reaching the optimal information size criterion (assuming α of 0.05, and β of 0.2) (<a href="./references#CD002854-bbs2-0102" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002854-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with mild cognitive impairment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with mild cognitive impairment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild cognitive impairment<br/> <b>Settings:</b> US and Canada<br/> <b>Intervention:</b> vitamin E (capsules 2000 IU/day in 2 divided doses)<br/> <b>Comparison:</b> placeb </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin E (capsules 2000 IU/day in 2 divided doses) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to Alzheimer's disease</b> </p> <p>Number of people progressing to AD</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> <br/> (224 to 383) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.79 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> <p>Mean change from baseline of ADAS‐Cog</p> <p>Scale from: 0 to 70</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncertainty about how missing data were handled. Study reports no significant difference between intervention and control groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Number of participants reporting ≥ 1 serious adverse event.</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>516<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse event rates not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Number of deaths over 36 months</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (6 to 66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.3 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Activities of daily living</b> </p> <p>Mean change from baseline using the ADCS<br/> Mild Cognitive Impairment Activities of Daily Living </p> <p>Scale from: 0 to 53</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncertainty about how missing data were handled. Study reports no significant difference between intervention and control groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer Disease Assessment Scale ‐ Cognitive Subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory;<b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due to imprecision. Evidence from a single study of modest size. This was supported by dichotomous data not reaching the optimal information size criterion (assuming α of 0.05, and β of 0.2) (<a href="./references#CD002854-bbs2-0102" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002854-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002854-sec-0030"></div> <section id="CD002854-sec-0031"> <h3 class="title" id="CD002854-sec-0031">Description of the condition</h3> <p>Dementia due to Alzheimer's disease (AD) is a progressive neurodegenerative condition in which people develop deficits in multiple cognitive domains, including memory, language and executive functioning, as well as a variety of emotional and behavioural symptoms. This leads to progressive functional impairment. AD causes huge emotional and financial burden to people, carers, and health and social care systems. Current treatments for AD have limited efficacy and cannot prevent progression of the condition. It is projected that 5.2% of the world's population will have dementia by 2050, equating to a worldwide prevalence of 131.5 million cases (<a href="./references#CD002854-bbs2-0129" title="PrinceM , WimoA , GuerchetM , AliG‐C , WuY‐T , PrinaM , Alzheimer's Disease International. World Alzheimer Report 2015. London: Alzheimer's Disease International, 2015. ">Prince 2015</a>). </p> <p>Mild cognitive impairment (MCI) is a condition of cognitive deficits which are not accompanied by significant impairment in the performance of activities of daily living and hence do not meet the diagnostic criteria for dementia. People with MCI are at increased risk of developing dementia (<a href="./references#CD002854-bbs2-0100" title="GanguliM , SnitzBE , SaxtonJA , ChangC‐CH , LeeC‐W , Vander BlitJ , et al. Outcomes of mild cognitive impairment by definition. Archives of Neurology2011;68(6):761‐7. ">Ganguli 2011</a>), although this is not considered inevitable (<a href="./references#CD002854-bbs2-0090" title="BruscoliM , LovestoneS . Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics2004;16(2):129‐40. ">Bruscoli 2004</a>). In 2011, it was estimated that between 10% and 20% of people over the age of 65 years meet criteria for MCI (<a href="./references#CD002854-bbs2-0125" title="PetersenCR . Mild cognitive impairment. New England Journal of Medicine2011;364(23):2227‐34. ">Petersen 2011</a>). </p> </section> <section id="CD002854-sec-0032"> <h3 class="title" id="CD002854-sec-0032">Description of the intervention</h3> <p>Vitamin E is a generic term for a group of eight naturally occurring, fat‐soluble chemical derivatives of tocopherol and tocotrienol. It occurs naturally in a variety of food substances including vegetable oils and fats, and in nuts and seeds, such as almonds and sunflower seeds. Alpha‐tocopherol is the most commonly studied compound and it has been the only form of vitamin E used in clinical trials in AD. According to the Food and Nutrition Board (FNB) at the Institute of Medicine of the National Academies (US), the recommended daily allowance for men and women over 14 years of age is 22.4 IU (15 mg of alpha‐tocopherol) (<a href="./references#CD002854-bbs2-0122" title="National Academy of Sciences. Institute of Medicine. Food and Nutrition Board. Vitamin E. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington DC: National Academy Press, 2000:186‐283. ">National Academy of Sciences 2000</a>). </p> <p>Vitamin E has a number of biological activities which vary with the form of vitamin E (<a href="./references#CD002854-bbs2-0087" title="BoccardiV , BaroniM , MangialascheF , MecocciP . Vitamin E family: role in the pathogenesis and treatment of Alzheimer's disease. Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions2016;2(3):182‐91. ">Boccardi 2016</a>). One of its functions is to act as a scavenger of free radicals by working as an antioxidant (<a href="./references#CD002854-bbs2-0142" title="UneriC , SariM , AkbogaJ , YukselM . Vitamin E‐coated tympanostomy tube insertion decrease the quantity of free radicals in tympanic membrane. Laryngoscope2006;116(1):140‐3. [PMID: 16481827] ">Uneri 2006</a>). Oxygen free radicals contain oxygen atoms with unpaired electrons and are highly reactive, damaging proteins, DNA and cell membranes unless rapidly 'quenched' by antioxidants. They are produced as by‐products of the body's metabolism as well as by radiation. As vitamin E is lipophilic, it can protect cell membranes and plasma lipoproteins from peroxyl radicals, which react preferentially with vitamin E (<a href="./references#CD002854-bbs2-0141" title="TraberMG , Stevens , JF . Vitamins C and E: beneficial effects from mechanistic perspective. Free Radical Biology &amp; Medicine2011;51:1000‐13. ">Traber 2011</a>). In particular, vitamin E is thought to inhibit the process of lipid peroxidation, which damages the polyunsaturated fatty acids essential to the integrity of cell membranes. Vitamin E's activity in protecting against the harmful effects of free radicals may be measured indirectly by assessing the state of the antioxidant‐oxidant system. Endogenous antioxidants such as glutathione provide an indication of the antioxidant status while the oxidised form of glutathione, glutathione disulphide (GSSG), and malondialdehyde (MDA) may provide an indication of the oxidative stress status and in particular lipid peroxidation. </p> <p>High doses of vitamin E (over 3000 IU/day) are considered toxic, and have been implicated in a variety of symptoms including fatigue, gastrointestinal cramps and diarrhoea. Further, there is an increasing body of evidence that vitamin E supplementation can cause adverse effects, even at lower doses. For example, vitamin E increases bleeding tendency and can potentiate the effect of aspirin (<a href="./references#CD002854-bbs2-0134" title="SteinerM , GlantzM , LekosA . Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. American Journal of Clinical Nutrition1995;62:1381S‐4S. ">Steiner 1995</a>). One meta‐analysis found that vitamin E supplementation, while reducing risk of ischaemic stroke by 10%, increased the risk of haemorrhagic stroke by 22% (<a href="./references#CD002854-bbs2-0132" title="SchürksM , GlynnRJ , RistPM , TzourioC , KurthT . Effects of vitamin E on stroke subtypes: meta‐analysis of randomised controlled trials. BMJ2010;341:c5702. [DOI: 10.1136/bmj.c5702] ">Schürks 2010</a>). Evidence from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) suggests that daily supplementation with vitamin E 400 IU in healthy men may significantly increase the risk of prostate cancer (<a href="./references#CD002854-bbs2-0110" title="KleinEA , ThompsonIM , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer. JAMA2011;306(14):1549‐56. ">Klein 2011</a>), and there is evidence from the Heart Outcomes Prevention Evaluation (HOPE) trial that vitamin E supplementation increases the risk of heart failure and hospitalisation for heart failure in people over 55 years of age with diabetes mellitus and vascular disease (<a href="./references#CD002854-bbs2-0112" title="LonnE , BoschJ , YusufS , SheridanP , PogueJ , ArnoldJM , et al. Effects of long‐term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA2005;293:1338‐47. ">Lonn 2005</a>). <a href="./references#CD002854-bbs2-0119" title="MillerER , Pastor‐BarriusoR , DalalD , RiemersmaRA , AppelLJ , GuallarE . Meta‐analysis: high‐dosage vitamin E supplementation may increase all‐cause mortality. Annals of Internal Medicine2005;142:37‐46. ">Miller 2005</a> carried out a meta‐analysis of 19 clinical trials testing vitamin E alone or in combination with other supplements. The median dose of vitamin E in these trials was 400 IU/day although the maximum dose was up to 2000 IU/day. The authors reported a statistically significant dose‐dependent relationship between vitamin E intake and all‐cause mortality. One Cochrane meta‐analysis also found that vitamin E given singly or combined with other antioxidants significantly increased mortality in 26 trials (risk ratio (RR) 1.04) (<a href="./references#CD002854-bbs2-0085" title="BjelakovicG , NikolovaD , GluudLL , SimonettiRG , GluudC . Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD007176] ">Bjelakovic 2010</a>). </p> </section> <section id="CD002854-sec-0033"> <h3 class="title" id="CD002854-sec-0033">How the intervention might work</h3> <p>There are both theoretical arguments and empirical findings to suggest that free radical damage may be one of the mechanisms causing neuronal degeneration in a range of conditions including ageing, MCI and AD. This evidence was summarised by <a href="./references#CD002854-bbs2-0101" title="GrundmanM . Vitamin E and Alzheimer disease: the basis for additional clinical trials. American Journal of Clinical Nutrition2000;71 Suppl:630S‐6S. ">Grundman 2000</a>. Many studies have found evidence of increased level of oxidative damage to neurons and mitochondrial DNA in AD and MCI (<a href="./references#CD002854-bbs2-0091" title="ButterfieldDA , CastegnaA , LauderbackCM , DrakeJ . Evidence that amyloid beta‐peptide‐induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiology of Aging2002;23(5):655‐64. [PMID: 12392766] ">Butterfield 2002</a>; <a href="./references#CD002854-bbs2-0104" title="HensleyK , HallN , SubramaniamR , ColeP , HarrisM , AksenovM , et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Journal of Neurochemistry1995;65:2146‐56. ">Hensley 1995</a>; <a href="./references#CD002854-bbs2-0115" title="MarcusDL , ThomasC , RodriguezC , SimberkoffK , TsaiJS , StrafaciJA , et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Experimental Neurology1998;150:40‐4. ">Marcus 1998</a>; <a href="./references#CD002854-bbs2-0117" title="MecocciP , MacGarveyU , BealMF . Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology1994;36:747‐51. ">Mecocci 1994</a>; <a href="./references#CD002854-bbs2-0118" title="MecocciP . Oxidative stress in mild cognitive impairment and Alzheimer's disease: a continuum. Journal of Alzheimer's Disease2004;6:159‐63. [PMID: 15096699] ">Mecocci 2004</a>; <a href="./references#CD002854-bbs2-0144" title="WangJ , XiongS , XieC , MarkesberyWR , LovellMA . Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of Neurochemistry2005;93(4):953‐62. [PMID: 15857398] ">Wang 2005</a>; <a href="./references#CD002854-bbs2-0145" title="WangJ , MarkesberyWR , LovellMA . Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. Journal of Neurochemistry2006;96(3):825‐32. [PMID: 16405502] ">Wang 2006</a>). Antioxidants, including vitamin E, improve cognitive functioning of aged rodents (<a href="./references#CD002854-bbs2-0133" title="SocciDJ , CrandallBM , ArendashGW . Chronic antioxidant treatment improves the cognitive performance of aged rats. Brain Research1995;693:88‐94. ">Socci 1995</a>), and protect against the effects of brain ischaemia (<a href="./references#CD002854-bbs2-0103" title="HaraH , KatoH , KogureK . Protective effect of alpha‐tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Research1990;510:335‐8. ">Hara 1990</a>) and of some neurotoxins (<a href="./references#CD002854-bbs2-0146" title="WortweinG , StackmanRW , WalshTJ . Vitamin E prevents the place learning deficit and the cholinergic hypofunction induced by AF64A. Experimental Neurology1994;125:15‐21. ">Wortwein 1994</a>). Transgenic mice overexpressing the amyloid precursor protein, implicated in AD, showed accelerated age‐associated brain degeneration (<a href="./references#CD002854-bbs2-0106" title="HsiaoKK , BorcheltDR , OlsonK , JohannsdottirR , KittC , YunisW , et al. Age‐related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron1995;15:1203‐18. ">Hsiao 1995</a>). Vitamin E can delay this deterioration (<a href="./references#CD002854-bbs2-0083" title="BehlC , DavisJ , ColeGM , SchubertD . Vitamin E protects nerve cells from amyloid‐beta protein toxicity. Biochemical and Biophysical Research Communication1992;186:944‐50. ">Behl 1992</a>; <a href="./references#CD002854-bbs2-0111" title="KoppalT , SubramaniamR , DrakeJ , PrasadMR , DhillonH , ButterfieldDA . Vitamin E protects against Alzheimer's amyloid peptide (25‐35)‐induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Research1998;786(1‐2):270‐3. ">Koppal 1998</a>; <a href="./references#CD002854-bbs2-0148" title="ZhouY , GopalakrishananV , RichardsonJS . Actions of neurotoxic beta‐amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. Journal of Neurochemistry1996;67:1419‐25. ">Zhou 1996</a>), and decrease oxidative DNA damage (<a href="./references#CD002854-bbs2-0088" title="BoothbyLA , DoeringPL . Vitamin C and vitamin E for Alzheimer's disease. Annals of Pharmacotherapy2005;39:2073‐9. [PMID: 16227450] ">Boothby 2005</a>). </p> <p>Central nervous tissue contains a high proportion of fatty material (lipid), and since vitamin E is fat‐soluble it can readily enter the brain (<a href="./references#CD002854-bbs2-0143" title="VatasseryGT , BrinMF , FahnS , KaydenHJ , TraberMG . Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. Journal of Neurochemistry1988;51:621‐3. ">Vatassery 1988</a>). In older‐adult population‐based studies, there have been reports of an association between low blood levels of vitamin E and impaired cognitive function (<a href="./references#CD002854-bbs2-0093" title="CherubiniA , MartinA , Andres‐LacuevaC , DiIorioA , LamponiM , MecocciP , et al. Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiology of Aging2005;26(7):987‐94. [DOI: dx.doi.org/10.1016/j.neurobiolaging.2004.09.002] ">Cherubini 2005</a>; <a href="./references#CD002854-bbs2-0124" title="PerrigWJ , PerrigP , StahelinHB . The relation between antioxidants and memory performance in the old and very old. Journal of American Geriatric Society1997;45:718‐24. ">Perrig 1997</a>). Mean levels of vitamin E in the blood and cerebrospinal fluid of people with AD were reported to be lower than normal in several reports (<a href="./references#CD002854-bbs2-0108" title="JeandelC , NicolasMB , DuboisF , Nabet‐BellevilleF , PeninF , CunyG . Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology1989;35:275‐82. ">Jeandel 1989</a>; <a href="./references#CD002854-bbs2-0109" title="Jimenez‐JimenezFJ , deBustosF , MolinaJA , Benito‐LeónJ , Tallón‐BarrancoA , GasallaT , et al. Cerebrospinal fluid levels of alpha‐tocopherol (vitamin E) in Alzheimer's disease. Journal of Neural Transmission1997;104:703‐10. ">Jimenez‐Jimenez 1997</a>; <a href="./references#CD002854-bbs2-0128" title="PolidoriMC , MecocciP . Plasma susceptibility to free radical‐induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. Journal of Alzheimers Disease2002;4(6):517‐22. [PMID: 12629261] ">Polidori 2002</a>; <a href="./references#CD002854-bbs2-0140" title="TohgiH , AbeT , NakanishiM , HamatoF , SasakiK , TakahashiS . Concentrations of alpha‐tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer type dementia. Neuroscience Letters1994;174:73‐6. ">Tohgi 1994</a>; <a href="./references#CD002854-bbs2-0147" title="ZamanZ , RocheS , FieldenP , FrostPG , NiriellaDC , CayleyAC . Plasma concentrations of vitamin A and E and Carotenoids in Alzheimer's disease. Age and Ageing1992;21:91‐4. ">Zaman 1992</a>), though not in all (<a href="./references#CD002854-bbs2-0080" title="AhlskogJE , UittiRJ , LowPA , TyceGM , NickanderKK , PetersenRC , et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement Disorders1995;10:566‐73. ">Ahlskog 1995</a>). Lower levels of both forms of vitamin E ‐ tocotrienols and tocopherols ‐ have been observed in the plasma of people with AD and MCI (<a href="./references#CD002854-bbs2-0114" title="MangialascheF , XuW , KivipeltoM , CostanziE , ErcolaniS , PigliautileM , et al. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiology of Aging2012;33(10):2282‐90. ">Mangialasche 2012</a>). However, lower levels of vitamin E in AD may be a consequence of the disease rather than a cause of it, due in part to an overall decreased general dietary intake especially as the disease advances (<a href="./references#CD002854-bbs2-0137" title="TabetN , MantleD , WalkerZ , OrrelM . Vitamins, trace elements, and antioxidant status in dementia disorders. International Psychogeriatrics2001;13(3):265‐75. ">Tabet 2001</a>; <a href="./references#CD002854-bbs2-0138" title="TabetN , MantleD , WalkerZ , OrrellM . Endogenous antioxidant activities in relation to concurrent vitamins A, C, and E intake in dementia. International Psychogeriatrics2002;12(1):7‐15. ">Tabet 2002</a>). </p> <p>Results from clinical trials of vitamin E in non‐AD neurodegenerative disorders have not been promising. For example, neither people with Parkinson's disease (<a href="./references#CD002854-bbs2-0123" title="The Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine1993;328:176‐83. ">Parkinson's SG 1993</a>; <a href="./references#CD002854-bbs2-0127" title="PhamDQ , PlakogiannisR . Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia and cataract: part 2. Annals of Pharmacotherapy2005;39(12):2065‐72. [PMID: 16288072] ">Pham 2005</a>) nor Huntington's disease (<a href="./references#CD002854-bbs2-0126" title="PeyserCE , FolsteinM , ChaseGA , StarksteinS , BrandtJ , CockrellJR , et al. Trial of d‐alpha‐tocopherol in Huntington's disease. American Journal of Psychiatry1995;152:1771‐5. ">Peyser 1995</a>) have shown a significant overall benefit from vitamin E supplementation. In this review, we focused specifically on the role of vitamin E in the treatment of AD and MCI. </p> </section> <section id="CD002854-sec-0034"> <h3 class="title" id="CD002854-sec-0034">Why it is important to do this review</h3> <p>It is estimated that 46.8 million people worldwide have a diagnosis of dementia, and this is predicted to rise to 131.5 million cases by 2050 (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#REF-Prince-2015" target="_blank">Prince 2015</a>), with AD being the most prevalent subtype. At present, there is no effective treatment for MCI or for dementia due to AD. Vitamin E continues to be used by some people as a non‐prescription supplement mainly because of its widely reported antioxidant properties and some previous positive findings. However, due to the potential health risks of taking vitamin E, it is important to determine whether vitamin E is an effective treatment of AD and MCI. This is an update of an earlier Cochrane Review, which was originally published in 2000 and was last updated in 2012. This review involved an updated search of the literature as well as changes to the conclusion, which better reflect emerging findings from vitamin E clinical trials in AD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002854-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002854-sec-0035"></div> <p>To assess the efficacy of vitamin E in the treatment of MCI and dementia due to AD.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002854-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002854-sec-0036"></div> <section id="CD002854-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002854-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all randomised, double‐blind trials in which vitamin E was compared with placebo in the treatment of people with MCI or dementia due to AD, or both. </p> </section> <section id="CD002854-sec-0039"> <h4 class="title">Types of participants</h4> <p>Participants with AD were diagnosed with probable AD according to internationally accepted diagnostic criteria including NINCDS‐ADRDA (National Institute of Neurological and Communicative Disorders and Stroke‐Alzheimer's Disease and Related Disorders Association (<a href="./references#CD002854-bbs2-0116" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services task Force on Alzheimer's Disease. Neurology1984;34:939‐44. ">McKhann 1984</a>), Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) (<a href="./references#CD002854-bbs2-0082" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Press, 1994. ">APA 1994</a>), or International Statistical Classification of Diseases and Related Health Problem, Tenth Revision (<a href="./references#CD002854-bbs2-0107" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research, 1993. www.who.int/entity/classifications/icd/en/GRNBOOK.pdf (accessed 10 October 2012). ">ICD‐10</a>). In the absence of consensus criteria for MCI, we accepted MCI defined according to published criteria such as those by <a href="https://archie.cochrane.org/sections/documents/view?version=z1511251250040647842844344156435%26format=REVMAN#STD-Petersen-2005" target="_blank">Petersen 2005</a>, or any other criteria with face validity. If only a subset of the study population was eligible for inclusion, then we sought and included data relating only to the eligible participants. </p> </section> <section id="CD002854-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies using any dosage of vitamin E or any of its constituent tocopherols or tocotrienols. A placebo comparator was required. Co‐administration of another drug with vitamin E was permitted if the same drug was also taken by the placebo group. There was no restriction on the dosage, mode of delivery or duration of the vitamin E intervention. </p> </section> <section id="CD002854-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We sought data on the primary and secondary outcomes listed below. For continuous outcomes, we included only data derived from validated, published scales. </p> <section id="CD002854-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002854-list-0001"> <li> <p>For MCI studies, development of, or time to development of, possible or probable AD.</p> </li> <li> <p>Cognitive function.</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Death.</p> </li> </ul> </p> </section> <section id="CD002854-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002854-list-0002"> <li> <p>Global measure of dementia severity and deterioration.</p> </li> <li> <p>Behavioural disturbance.</p> </li> <li> <p>Mood.</p> </li> <li> <p>Activities of daily living.</p> </li> <li> <p>Carer burden.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Permanent physical disability.</p> </li> <li> <p>Institutionalisation.</p> </li> </ul> </p> </section> </section> </section> <section id="CD002854-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002854-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>) ‐ the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 22 April 2016. The search terms used were: "Vitamin E", vitamin‐E, alpha‐tocopherol. </p> <p>ALOIS is maintained by the Trials Search Co‐ordinator of the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies are identified from:   </p> <p> <ul id="CD002854-list-0003"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and LILACS; </p> </li> <li> <p>monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly searches of the Cochrane Library’s Central Register of Controlled Trials (CENTRAL); </p> </li> <li> <p>six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses and Australasian Digital Theses. </p> </li> </ul> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the 'methods used in reviews' section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>Additional searches were performed in the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used can be seen in <a href="./appendices#CD002854-sec-0119">Appendix 1</a>. </p> </section> <section id="CD002854-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of included studies to identify any additional studies.</p> </section> </section> <section id="CD002854-sec-0047"> <h3 class="title" id="CD002854-sec-0047">Data collection and analysis</h3> <section id="CD002854-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NF and DL) independently examined the title and abstract of the papers identified by the search and selected and retrieved them for their relevance to the review. We resolved any disagreements concerning inclusion by discussion among all review authors until a decision was made. </p> </section> <section id="CD002854-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (NF and DL for descriptive data, NF and NT for outcome data) independently extract data for all authors. We attempted to collect the following data: </p> <p> <ul id="CD002854-list-0004"> <li> <p>report ‐ author, year and source of publication;</p> </li> <li> <p>study ‐ study setting;</p> </li> <li> <p>participants ‐ demographics, diagnostic criteria for AD or MCI, exclusion criteria, other concomitant medical conditions or medications that may affect cognition; </p> </li> <li> <p>research design and features ‐ sampling mechanism, treatment assignment mechanism, blinding, dropout rates, length of follow‐up, pertinent design features (e.g. cross‐over design); </p> </li> <li> <p>intervention ‐ type, duration, dose, timing, mode of delivery;</p> </li> <li> <p>outcome measures;</p> </li> <li> <p>results ‐ number of participants randomised, outcome data.</p> </li> </ul> </p> <p>For each outcome measure, we sought data on every participant randomised We preferred intention‐to‐treat (ITT) data but if these were not available, we extracted data on participants who completed treatment. We did not extract data for any non‐randomised titration periods or any open‐label follow‐on phases. </p> <p>For continuous data, we extracted the means, standard deviation (SD) and number of participants in each treatment group at each time point. We extracted change from baseline data if endpoint data were unavailable. For binary data, the data extracted was the number of participants with each outcome in each treatment group at each time point. For ordinal data, there were two possible approaches. If ordinal scale data appeared to be approximately normally distributed or if the analysis that the investigators performed suggested that parametric tests were appropriate, then ewe treated the outcome measures as continuous data. The second approach, which may not exclude the first, was to concatenate into two categories that best represent the contrasting states of interest, and to treat the variable as binary. For time‐to‐event data, we used a hazard ratio (HR). </p> </section> <section id="CD002854-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NF and DL) assessed risk of bias for each included study independently. This was assessed based on guidance from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002854-bbs2-0105" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the following criteria: </p> <p> <ul id="CD002854-list-0005"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (participants);</p> </li> <li> <p>blinding (investigators);</p> </li> <li> <p>incomplete outcome reporting;</p> </li> <li> <p>selective outcome reporting.</p> </li> </ul> </p> <p>For each study, we gave a risk of bias rating ('Low risk', 'Unclear risk' or 'High risk') for each of the above criteria. Empirical research has shown that lack of adequate allocation concealment may be associated with bias. Trials with unclear concealment measures have been shown to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, but less pronounced than inadequately concealed trials (<a href="./references#CD002854-bbs2-0092" title="ChalmersTC , CelanoP , SacksHS , SmithHJr . Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine1983;309:1358‐61. ">Chalmers 1983</a>; <a href="./references#CD002854-bbs2-0131" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>). Thus, we included trials if they conformed to 'Low risk' or 'Unclear risk' allocation risk categories, while we excluded trials falling into the 'High risk' category. </p> </section> <section id="CD002854-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For studies with continuous outcome measures, we calculated mean differences (MD) or standardised mean differences (SMD) with 95% confidence intervals (CI). For binary outcome measures, we calculated RRs. For time‐to‐event outcome measures, we calculated HRs. </p> </section> <section id="CD002854-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis.</p> </section> <section id="CD002854-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>An ITT analysis was carried out where possible. In cases where only completers' data were available, we explored the impact of the missing data on the findings, where possible. When appropriate, the review authors contacted relevant study authors to request missing information. </p> </section> <section id="CD002854-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Owing to the clearly significant clinical and methodological heterogeneity between studies, we performed no statistical tests for heterogeneity. As such, data did not lend itself to performing a meta‐analysis. However, we carried out critical interpretive synthesis of data for individual studies. </p> </section> <section id="CD002854-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>There were an insufficient number of studies identified to make an overall quantitative assessment. We assessed biases for individual studies. </p> </section> <section id="CD002854-sec-0056"> <h4 class="title">Data synthesis</h4> <p>It was not possible to synthesise and compare data across studies as there were no comparable outcome measures. We carried out a critical interpretive synthesis of data for individual studies separately. We included 'Summary of findings' tables. </p> </section> <section id="CD002854-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Although not specified in the protocol, we extracted and reported data for a subgroup analysis carried out in one included study. The subgroups were participants who did or did not show a decline in markers of oxidative stress in response to vitamin E treatment. This subgroup was considered important to include as a reduction of oxidative stress is thought to be the mechanism by which vitamin E may affect cognition. </p> </section> <section id="CD002854-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was planned if a sufficient number of comparable studies were identified. </p> <section id="CD002854-sec-0059"> <h5 class="title">Presentation of results ‐ 'Summary of findings' tables</h5> <p>We used the GRADE approach to assess the quality of the supporting evidence behind the treatment effects presented in this review (<a href="./references#CD002854-bbs2-0102" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). For each comparison, we presented key outcomes in a 'Summary of findings' table including, for each outcome, a summary of the amount of data, the magnitude of the effect size and the quality of the evidence. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002854-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002854-sec-0060"></div> <section id="CD002854-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD002854-sec-0130" title="">Characteristics of included studies</a> and <a href="./references#CD002854-sec-0131" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD002854-sec-0062"> <h4 class="title">Results of the search</h4> <p>Only four trials met the inclusion criteria: <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009;</a><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>; and <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>. Three were trials of alpha‐tocopherol (vitamin E) for the treatment of dementia due to AD (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>) and one was a trial of alpha‐tocopherol to delay progression from amnestic MCI to dementia (<a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>). See <a href="#CD002854-fig-0001">Figure 1</a> for the study flow diagram of included studies. </p> <div class="figure" id="CD002854-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for study for the search April 2016." data-id="CD002854-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for study for the search April 2016.</p> </div> </div> </div> </section> <section id="CD002854-sec-0063"> <h4 class="title">Included studies</h4> <section id="CD002854-sec-0064"> <h5 class="title">Treatment of dementia due to Alzheimer's disease</h5> <p>The primary purpose of the first treatment study was to determine whether alpha‐tocopherol (vitamin E), selegiline (a monoamine oxidase inhibitor) or a combination of the two agents would slow the clinical deterioration associated with AD (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Sano-1996" target="_blank">Sano 1996</a>). There were four groups: placebo, vitamin E (2000 IU total daily dose divided into two doses), selegiline and selegiline plus vitamin E. The study recruited 341 participants with a diagnosis of probable AD dementia of moderate severity (Clinical Dementia Rating (CDR) 2 (<a href="./references#CD002854-bbs2-0084" title="BergL . Clinical Dementia Rating (CDR). Psychopharmacology Bulletin1988;24:637‐9. ">Berg 1988</a>)) from 23 centres in the US. We considered only the placebo (n = 84) and vitamin E (n = 85) groups in this review. Assessments were conducted one month after enrolment and at three‐monthly intervals for two years. The primary outcome was the survival time to any one of four end points; death, institutionalisation, change in severity of dementia to a CDR of three or loss of two basic activities of daily living. After the primary end point was reached, every effort was made to continue further assessment of the secondary outcomes if possible. The secondary outcomes were the Cognitive section of the Alzheimer's Disease Assessment Scale (ADAS‐Cog) (<a href="./references#CD002854-bbs2-0130" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer's disease. American Journal of Psychiatry1984;141:1356‐64. ">Rosen 1984</a>), the Mini‐Mental State Examination (MMSE) (<a href="./references#CD002854-bbs2-0098" title="FolsteinMF , FolsteinSE , McHughPR . 'Mini‐Mental State': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. ">Folstein 1975</a>), the Blessed Dementia Scale (BDS) (<a href="./references#CD002854-bbs2-0086" title="BlessedB , TomlinsonBE , RothM . The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. British Journal of Psychiatry1968;114:797‐811. ">Blessed 1968</a>), the Dependence Scale (DS) (<a href="./references#CD002854-bbs2-0135" title="SternY , AlbertSM , SanoM , RichardsM , MillerL , FolsteinM , et al. Assessing patient dependence in Alzheimer's disease. Journal of Gerontology1994;49(5):M216‐22. ">Stern 1994</a>), the Behavior Rating Scale for Dementia (BRSD) (<a href="./references#CD002854-bbs2-0139" title="TariotPN , MackJL , PattersonMB , EdlandSD , WeinerMF , FillenbaumG , et al. The Behavior Rating Scale for Dementia Consortium to establish a registry for Alzheimer's disease. American Journal of Psychiatry1995;152:1349‐57. ">Tariot 1995</a>), and adverse events. The primary analysis compared survival to end point for each of the three treatment groups in comparison with the placebo group, using Kaplan‐Meier estimation and log‐rank tests with no correction for other factors or variables, and the Cox proportional hazards model including covariates. A small number of participants were lost to follow‐up without having reached a primary end point (placebo 6/84, vitamin E 8/85). </p> <p>The purpose of the second treatment study was to explore the effects of vitamin E on AD progression and markers of oxidative stress (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Lloret-2009" target="_blank">Lloret 2009</a>). Vitamin E 800 IU or placebo was given daily for six months. There were 57 participants diagnosed with probable AD. All AD participants were taking a cholinesterase inhibitor and were not taking any other antioxidant medication. Assessments were conducted on the first day of enrolment and after six months. Oxidative stress was assessed in two ways. The first method used blood concentrations of the oxidised glutathione molecule, GSSG, with greater levels indicating greater oxidative stress. GSSG was also assessed as a ratio with the antioxidant molecule, glutathione. The second method measured the blood marker MDA as a marker of lipid peroxidation, which is a strong indicator of oxidative damage. AD progression was measured by the Clock Drawing Test (<a href="./references#CD002854-bbs2-0136" title="SunderlandT , HillJL , MellowAM , LawlorBA , GundersheimerJ , NewhousePA , et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. Journal of the American Geriatrics Society1989;37:725‐9. ">Sunderland 1989</a>), the BDS and MMSE. The primary analysis was to compare performance on the cognitive tasks in relation to the effects of vitamin E on oxidative stress. The effects of vitamin E on oxidative stress markers were investigated using a Mann‐Whitney test to compare GSSG and MDA values at the beginning and the end of the study in both the placebo and active treatment groups. Vitamin E‐treated participants were divided into responders and non‐responders according to whether vitamin E was effective or not in reducing markers of oxidative stress. The responder, non‐responder and placebo group means were compared using a Kruskal‐Wallis test. Comparison between groups was also undertaken following removal of participants with cerebrovascular disease. To determine the effect of modifying oxidative stress on cognitive performance, the relationship between MMSE change and GSSG change in participants treated with vitamin E was assessed using Spearman's coefficient of correlation. We contacted two authors of the <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Lloret-2009" target="_blank">Lloret 2009</a> study for additional information, but following an initial response from one author, we received no additional responses. </p> <p>The purpose of the third treatment study was to determine if alpha tocopherol (vitamin E), memantine, or both slowed the progression of mild to moderate AD (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>). In a double‐blind, placebo‐controlled randomised controlled trial (RCT), 613 people with mild to moderate AD were randomly assigned to one of four groups: alpha tocopherol (2000 IU total daily divided into two doses), memantine 20 mg/day, alpha tocopherol plus memantine or placebo. We considered only the placebo (n = 152) and vitamin E (n = 152) groups in this review. All participants were recruited in the US and had a diagnosis of possible or probable AD of mild to moderate severity, as defined by a MMSE score between 12 and 26. Duration of treatment ranged from six months to four years and participants were assessed every six months. The primary outcome was the Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS‐ADL) scale (<a href="./references#CD002854-bbs2-0099" title="GalaskoD , BennetD , SanoM , MarsonD , KayeJ , EdlandSD . Alzheimer's Disease Cooperative Study. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community‐dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Disease and Associated Disorders2006;20:s152‐69. [DOI: 10.1097/01.wad.0000213873.25053.2b] ">Galasko 2006</a>). Secondary outcomes were the ADAS‐Cog, Neuropsychiatric Inventory (NPI) (<a href="./references#CD002854-bbs2-0095" title="CummingsJL , MegaM , GrayK , Rosenberg‐ThompsonS , CarusiDA , GornbeinJ . The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology1994;44(12):2308. ">Cummings 1994</a>), the Caregiver Activity Survey (CAS) (<a href="./references#CD002854-bbs2-0096" title="DavisKL , MarinDB , KaneR , PatrickD , PeskindER , RaskindMA , et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. International Journal of Geriatric Psychiatry1997;12(10):978‐88. ">Davis 1997</a>), the DS and adverse events. Participants and their carers were asked specifically about participant falls, syncope and congestive heart failure as these were linked to high‐dose alpha tocopherol in previous trials (<a href="./references#CD002854-bbs2-0112" title="LonnE , BoschJ , YusufS , SheridanP , PogueJ , ArnoldJM , et al. Effects of long‐term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA2005;293:1338‐47. ">Lonn 2005</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). Serious adverse events were coded on the basis of Medical Dictionary for Regulatory Activities. A longitudinal repeated‐measure mixed‐effects model adjusted for medical centre as a random effect and for baseline ADCS‐ADL. </p> </section> <section id="CD002854-sec-0065"> <h5 class="title">Prevention of progression of cognitive impairment</h5> <p>The primary purpose of the single MCI study was to determine whether treatment with vitamin E 2000 IU/day or donepezil in people with the amnestic form of MCI decreased the conversion rate into dementia due to AD (<a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>). There were three treatment groups: vitamin E, donepezil and placebo. All participants were also taking a multivitamin. This review included the vitamin E and the placebo groups only. Out of 769 participants enrolled from 69 sites in the US and Canada, 516 received either placebo or vitamin E. The secondary outcomes were scores on various measures: the MMSE (<a href="https://archie.cochrane.org/sections/documents/view?version=z1603091745176301345482343907844%26format=REVMAN#REF-Folstein-1975" target="_blank">Folstein 1975</a>), ADAS‐Cog (<a href="https://archie.cochrane.org/sections/documents/view?version=z1603091745176301345482343907844%26format=REVMAN#REF-Rosen-1984" target="_blank">Rosen 1984</a>), CDR (Sum of Boxes), the Alzheimer's Disease Assessment Scale Mild Cognitive Impairment Activities of Daily Living (ADCS‐MCI‐ADL) scale, the Global Deterioration Scale, a neuropsychological battery and adverse events. For further details about the study design refer to the <a href="./references#CD002854-sec-0130" title="">Characteristics of included studies</a> table. </p> <p>The relevant primary analysis in the paper used the Cox proportional hazards model to determine whether there was a significant reduction in time to progression to AD among participants treated with vitamin E compared with participants given placebo. Participants were included on an ITT basis. Several baseline variables were included in the analysis as covariates. The secondary outcomes were examined using analysis of covariance for the change in scores without correction for multiple comparisons. Missing values were imputed using a projection method considered appropriate for assessing responses among people with neurodegenerative diseases (<a href="./references#CD002854-bbs2-0081" title="AisenPS , SchaferKA , GrundmanM , PfeifferE , SanoM , DavisKL , et al. the Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA2003;289(21):2819‐26. ">Aisen 2003</a>). </p> </section> </section> <section id="CD002854-sec-0066"> <h4 class="title">Excluded studies</h4> <p>Following the latest search (April 2016), we initially excluded 46 articles based on the screening of the abstract and title. Of the 11 remaining articles, we excluded one because it did not use a suitable control intervention for our question (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Naeini-2014" target="_blank">Naeini 2014</a>), two because the study population was ineligible (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Kryscio-2013a" target="_blank">Kryscio 2013a</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-MacPherson-2012" target="_blank">MacPherson 2012</a>), and three because they were not RCTs (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Corbett-2014" target="_blank">Corbett 2014</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Evans-2014" target="_blank">Evans 2014</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Hermann-2014" target="_blank">Hermann 2014</a>). The five remaining articles all described one study which was eligible for inclusion (<a href="https://archie.cochrane.org/sections/documents/view?version=z1607181652186511566797933251616%26format=REVMAN#STD-Dysken-2014" target="_blank">Dysken 2014</a>), however, we subsequently excluded two because they were identified as duplicates. Details of the excluded studies are provided in <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD002854-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD002854-fig-0002">Figure 2</a> for the summary of the risk of bias, and <a href="#CD002854-fig-0003">Figure 3</a> for the 'Risk of bias' graph. See <a href="./references#CD002854-sec-0130" title="">Characteristics of included studies</a> table for further details of included studies. </p> <div class="figure" id="CD002854-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002854-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD002854-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002854-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD002854-sec-0068"> <h4 class="title">Allocation</h4> <p>We judged that all four studies had a low risk of bias in terms of random sequence generation. </p> <p>Only <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Dysken-2014" target="_blank">Dysken 2014</a> sufficiently described their method of allocation concealment. In the other three studies, the means of ensuring allocation concealment was unclear. However, we considered it sufficiently likely that allocation was concealed to include the studies. </p> </section> <section id="CD002854-sec-0069"> <h4 class="title">Blinding</h4> <p>All studies report that they were double‐blinded, though no study described how this was maintained throughout the studies or whether blinding was successful. However, <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> did use placebo capsules with identical appearance to the vitamin E capsules, so we considered this to have a low risk of bias. We judged the remaining studies to have an unclear risk of performance bias. </p> <p>We considered all studies at unclear risk of detection bias because of a lack of information on blinding of outcome assessors. </p> </section> <section id="CD002854-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>Missing data was balanced across groups in <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>, thus we judged risk of bias to be low. <a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> reported using an ITT analysis with an appropriate imputation method to deal with missing data and stated that demographic and neuropsychological outcomes did not differ significantly between missing and non‐missing participants. However, it was difficult to tell how the authors had handled data from participants who had developed dementia and switched to open‐label donepezil. Only 42% of participants randomised to vitamin E and 46% randomised to placebo completed the study on their allocated treatment. We judged the study to have an unclear risk of attrition bias. <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Sano-1996" target="_blank">Sano 1996</a> reported the attrition rate but did not give reasons. In addition, <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> only reported attrition up to the point a participant reached one of their primary end points, therefore we judged it to be at high risk of bias for our outcomes of interest. <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Lloret-2009" target="_blank">Lloret 2009</a> reported a very high attrition rate and did not give reasons; we judged it to be at high risk of bias. </p> </section> <section id="CD002854-sec-0071"> <h4 class="title">Selective reporting</h4> <p>All studies reported outcomes stated in their protocol although often in insufficient detail for our purposes. <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Lloret-2009" target="_blank">Lloret 2009</a> tended to report significance values alone, without means and SDs. Similarly, <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> did not report SDs for the changes in score of their secondary outcomes. Thus, we judged the <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> and <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> studies to have an unclear risk of bias in this domain. We judged the remaining studies to have a low risk of reporting bias. </p> </section> <section id="CD002854-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>We found no other sources of bias.</p> </section> </section> <section id="CD002854-sec-0073"> <h3 class="title" id="CD002854-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD002854-tbl-0001"><b>Summary of findings for the main comparison</b> Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with Alzheimer's disease</a>; <a href="./full#CD002854-tbl-0002"><b>Summary of findings 2</b> Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with mild cognitive impairment</a> </p> <section id="CD002854-sec-0074"> <h4 class="title">Vitamin E for dementia due to Alzheimer's disease</h4> <p>Three studies assessed the efficacy of vitamin E in people with dementia due to AD (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). For a summary of findings related to the treatment of AD, see <a href="./full#CD002854-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p><a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Sano-1996" target="_blank">Sano 1996</a> had four treatment groups of which the groups receiving placebo only and vitamin E only were relevant to this review. Six of 84 participants in the placebo group and 8 of 85 participants in the vitamin E group were lost to follow‐up without reaching one of the predefined primary end points of death, institutionalisation, change in severity of dementia to a CDR score of three, or loss of two basic activities of daily living, but there was no information on the time points at which these participants were lost or on how many participants were lost to follow‐up after a primary end point. </p> <p><a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=715499091710332585%26versionPK1=z1210121332597483750137640631974%26versionPK2=z1511251250040647842844344156435#STD-Lloret-2009" target="_blank">Lloret 2009</a> divided participants treated with vitamin E into two groups depending on changes in oxidative stress markers with treatment. These groups had not been defined in advance of data collection. Participants who showed a decrease in GSSG values of more than 10 nmol/mL of blood after six months of vitamin E treatment were termed 'responders' and participants who did not were termed 'non‐responders'. They reported 'completers' results only (33/57 randomised participants). </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> had four treatment groups, but we evaluated only data for the vitamin E and placebo groups for this review (<a href="https://archie.cochrane.org/sections/documents/view?version=z1608241148580143794191867631690%26format=REVMAN#STD-Dysken-2014" target="_blank">Dysken 2014</a>). There was a wide range of durations of follow‐up within the trial (six to 48 months), with participants completing at least one follow‐up being included in the analysis. The final analysis included 140/152 (92.1%) participants in the vitamin E group and 140/152 (92.1%) participants in the placebo group. The authors calculated a least squares (LS) mean change from baseline in each treatment group and reported this with its standard error (SE). <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> also reported results as a mean annual rate of change. For each relevant continuous outcome variable, we extracted the LS mean change from baseline, and derived SDs from reported SEs. We then calculated the MD (with 95% CI) between vitamin E and placebo groups. </p> <section id="CD002854-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD002854-sec-0076"> <h6 class="title">Cognitive function</h6> <p>We were unable to extract the data we had specified for cognitive function for <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>. Although the ADAS‐Cog and MMSE were secondary outcomes in the trial, only mean change scores to the time point where a participant was last assessed were reported and participants had been assessed over varying and unidentified time spans. SDs were not reported. The authors reported that changes from baseline score on the MMSE and the ADAS‐Cog did not differ significantly among the four groups. </p> <p><a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> measured cognition using the MMSE and the Clock Drawing Test, though we were unable to extract the data. The authors did not report means and SDs of their cognitive outcomes. There were no data on cognitive measures in the vitamin E‐treated group as a whole. </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> measured cognition using the ADAS‐Cog and MMSE. At six to 48 months, participants taking vitamin E had a smaller increase from baseline on the ADAS‐Cog (an increase in score representing worsening cognitive function) than participants taking placebo, but the result was uncertain and unlikely to be of clinical importance (completers: MD ‐1.81, 95% CI ‐3.75 to 0.13, P = 0.07, 1 study, n = 272; moderate quality evidence, downgraded due to imprecision because data were from a single small study). There was no evidence of a difference between groups in cognitive function measured with the MMSE (where a decrease represents worsening function) (completers: MD 0.19, 95% CI ‐0.72 to 1.10, P = 0.68, 1 study, n = 273; moderate quality evidence, downgraded due to imprecision). </p> </section> <section id="CD002854-sec-0077"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> did not fully report adverse events. A total of 49 categories of adverse events were defined but the only results initially reported were for three categories (dental events, falls and syncopal episodes), in which there were significant differences between one or more of the treatment groups and the placebo group. However, once the authors adjusted for multiple comparisons, there were no significant differences between groups. </p> <p><a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> did not report adverse events. We requested additional information but this was not made available. </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> found no evidence of a difference between vitamin E and placebo groups in the number of participants reporting any adverse event or the number reporting at least one severe adverse event. The numbers of participants reporting adverse events during the study were 91/152 (59.9%) in the vitamin E group and 89/152 (58.6%) in the placebo group (RR 1.02, 95% CI 0.85 to 1.23, P = 0.82, 1 study, n = 304; moderate quality evidence, downgraded due to imprecision). The number of participants reporting at least one severe adverse event were 82/152 (54.0%) in the vitamin E group and 95/152 (62.5%) in the placebo group over the 48‐month trial (RR 0.86, 95% CI 0.71 to 1.05, P = 0.13, 1 study, n = 304; moderate quality evidence, downgraded due to imprecision). </p> </section> <section id="CD002854-sec-0078"> <h6 class="title">Death</h6> <p>In <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>, participants remained in the study until they reached one of the four predefined end points, one of which was death. In both vitamin E and placebo groups, 12% of participants died. The authors also reported that treatment had no effect on the cause of death. </p> <p><a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> did not report deaths. We requested additional information but this was not made available. </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> found no evidence of a difference between vitamin E and placebo groups in the number of deaths. There were 26/152 (17.1%) deaths in the vitamin E group compared to 31/152 (20.4%) deaths in the placebo group over the 48‐month trial (RR 0.84, 95% CI 0.52 to 1.34, P = 0.46, 1 study, n = 304; moderate quality evidence, downgraded due to imprecision). </p> </section> </section> <section id="CD002854-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD002854-sec-0080"> <h6 class="title">Global measure of dementia severity and deterioration</h6> <p>None of the studies measured dementia severity and deterioration (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). </p> </section> <section id="CD002854-sec-0081"> <h6 class="title">Behavioural disturbance</h6> <p>In <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>, we were unable to extract the data for behavioural disturbances despite these being measured as secondary outcomes in the trial. Only the mean change scores to the time point where a participant was last assessed were reported and participants had been assessed over varying and unidentified time spans. SDs were not reported. </p> <p><a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> did not measure behavioural disturbance. </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> found that neuropsychiatric symptoms increased slightly more in the placebo group than in the vitamin E group over six to 48 months using the NPI but the result was uncertain and unlikely to be of clinical importance (completers: MD ‐1.47, 95% CI ‐4.26 to 1.32, P = 0.30, 1 study, n = 280; moderate quality evidence, downgraded due to imprecision). </p> </section> <section id="CD002854-sec-0082"> <h6 class="title">Mood</h6> <p>None of the studies measured mood (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). </p> </section> <section id="CD002854-sec-0083"> <h6 class="title">Activities of daily living</h6> <p>In <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>, we were unable to extract the data we had specified for activities of daily living, despite these being measured as secondary outcomes in the trial. Only the mean change scores to the time point where a participant was last assessed were reported and participants had been assessed over varying and unidentified time spans. SDs were not reported. The authors reported that there was significantly less decline in activities of daily living, as measured by the BDS and DS, in the vitamin E compared to the placebo group, but no significant difference between groups on the BRSD. </p> <p><a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> measured activities of daily living using the BDS. The authors did not report means and SDs, and therefore we were unable to extract the data. </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> measured activities of daily living using the ADCS‐ADL. Participants receiving vitamin E showed less functional decline on the ADCS‐ADL than participants receiving placebo at six to 48 months (completers: MD 3.15, 95% CI 0.07 to 6.23, P = 0.04, 1 study, n = 280; moderate quality evidence, downgraded due to imprecision). </p> </section> <section id="CD002854-sec-0084"> <h6 class="title">Carer burden</h6> <p>None of the studies measured carer burden (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). </p> </section> <section id="CD002854-sec-0085"> <h6 class="title">Quality of life</h6> <p>None of the studies measured quality of life (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). </p> </section> <section id="CD002854-sec-0086"> <h6 class="title">Permanent physical disability</h6> <p>None of the studies measured permanent physical disability (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). </p> </section> <section id="CD002854-sec-0087"> <h6 class="title">Institutionalisation</h6> <p><a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> reported that participants receiving vitamin E treatment significantly delayed institutionalisation compared to participants receiving placebo (RR 0.42, no CI reported; P = 0.003). </p> <p>Neither <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> nor <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> measured institutionalisation. </p> </section> </section> <section id="CD002854-sec-0088"> <h5 class="title">Other study outcomes</h5> <p><a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> reported the number in each outcome group who reached one of their primary end points (death, institutionalisation, change in severity of dementia to a CDR score of three or loss of two basic activities of daily living) within two years; this was 45/85 (53%) of participants in the vitamin E group and 58/84 (69%) in the placebo group. Because the trial was limited in time, an analysis comparing a count of events without taking into account their timing is less precise than the survival analysis reported by <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>. Using Kaplan‐Meier estimation and log‐rank testing in their primary analysis, <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> found no significant difference in survival time to one of the four end points between the vitamin E and placebo groups (RR 0.70, no CI reported; P = 0.08). However, the study groups differed in baseline MMSE scores and these were correlated with clinical course. The vitamin E group began with a mean MMSE of 11.3 (SD 5.7) and the placebo group with a mean MMSE of 13.3 (SD 4.9). When the analysis was repeated using the Cox proportional hazards model and controlling for baseline MMSE, there emerged a significant difference favouring vitamin E (RR 0.47, no CI reported; P = 0.001). </p> <p>The primary outcomes reported by <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> were the percentage change in performance from baseline to six months on the BDS, Clock Drawing Test and MMSE, compared across responders (n = 9), non‐responders (n = 10) and placebo‐treated groups (n = 14), where participants who showed a decrease in GSSG values of more than 10 nmol/mL of blood after six months of vitamin E treatment were termed 'responders' and participants who did not were termed 'non‐responders'. We found no evidence that these groups had been defined before data collection. The authors reported no significant difference between groups on the Clock Drawing Test or BDS in an analysis of 'completers' only. The MMSE score increased in the responder group but decreased in the placebo group and more so in the non‐responders. There was a significant difference between the two vitamin E‐treated groups on MMSE change score (P &lt; 0.05). The responders did not differ significantly from the placebo‐treated group. The decline in MMSE in the non‐responders was significantly greater than in the placebo group (P &lt; 0.05). <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> also reported a negative correlation between change in MMSE score and change in blood levels of GSSG from baseline to six months; that is, there was a greater decline in cognitive performance in people with AD whose blood GSSG levels stayed higher (reflecting higher oxidative stress). </p> <p><a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> reported that for functional decline, the mean treatment effect of 3.15 units on the ADCS‐ADL, favouring participants receiving vitamin E, translates into a clinically meaningful delay in progression of 6.2 months (95% CI 5.4 to 7.4), based on the rate of change in the control group. </p> </section> </section> <section id="CD002854-sec-0089"> <h4 class="title">Vitamin E for mild cognitive impairment</h4> <p>One study assessed vitamin E in people with MCI (<a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>). For a summary of findings for the treatment of MCI, see <a href="./full#CD002854-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD002854-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD002854-sec-0091"> <h6 class="title">Development of, or time to development of, possible or probable Alzheimer's disease</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> found no evidence of an effect of vitamin E on the numbers of participants with MCI who progressed to possible or probable AD. As their primary outcome, <a href="https://archie.cochrane.org/sections/documents/view?version=z1608241148580143794191867631690%26format=REVMAN#STD-Petersen-2005" target="_blank">Petersen 2005</a> reported that 33/257 participants in the vitamin E group and 38/259 participants in the placebo group progressed to possible or probable AD in the first 12 months (RR 1.02, 95% CI 0.96 to 1.10, P = 0.05, 1 study, n = 516). By 36 months, 76/257 participants in the vitamin E group and 73/259 in the placebo group had progressed to AD (RR 1.03, 95% CI 0.79 to 1.35, P = 0.81, 1 study, n = 516). We considered this moderate quality evidence, downgraded due to imprecision. </p> </section> <section id="CD002854-sec-0092"> <h6 class="title">Cognitive function</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> reported no significant difference between those receiving vitamin E and placebo on the change from baseline of the MMSE, ADAS‐Cog and modified ADAS‐Cog. However, it was difficult to tell how missing data had been handled and no sample size was reported, so we were unable to conduct an analysis. </p> </section> <section id="CD002854-sec-0093"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not fully report adverse events and therefore we were unable to extract the data we required. The authors reported the rates of 10 types of adverse events that occurred in at least 5% of participants in the vitamin E and at least two times in the placebo group during the double‐blind phase of the study. Diarrhoea and cataract extraction were the most frequently reported adverse events in the vitamin E group. Neither of these adverse events differed significantly in frequency between the vitamin E and placebo groups (P &gt; 0.05). Overall, 66/257 participants discontinued in the vitamin E group and 72/259 participants discontinued treatment in the placebo group. Reasons were not given by group, but in the study as a whole, most discontinuations resulted from withdrawal of consent or adverse events. </p> </section> <section id="CD002854-sec-0094"> <h6 class="title">Death</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> reported that five deaths occurred in each of the vitamin E and placebo groups during the 36‐month double‐blind phase (RR 1.01, 95% CI 0.30 to 3.44, P = 0.99, 1 study, n = 516; moderate quality evidence, downgraded due to imprecision). All deaths were deemed to be unrelated to treatment. </p> </section> </section> <section id="CD002854-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD002854-sec-0096"> <h6 class="title">Global measure of dementia severity and deterioration</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> reported no significant difference between those receiving vitamin E and placebo on change scores of the CDR Sum of Boxes or the Global Deterioration Scale. However, it was difficult to tell how missing data had been handled and no sample size was reported, so we were unable to conduct an analysis. </p> </section> <section id="CD002854-sec-0097"> <h6 class="title">Behavioural disturbance</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure behavioural disturbance. </p> </section> <section id="CD002854-sec-0098"> <h6 class="title">Mood</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure mood. </p> </section> <section id="CD002854-sec-0099"> <h6 class="title">Activities of daily living</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> reported no significant difference between those receiving vitamin E and placebo on change scores of the ADCS MCI‐ADL. However, it was difficult to tell how missing data had been handled and no sample size was reported, so we were unable to conduct an analysis. </p> </section> <section id="CD002854-sec-0100"> <h6 class="title">Carer burden</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure carer burden. </p> </section> <section id="CD002854-sec-0101"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure quality of life. </p> </section> <section id="CD002854-sec-0102"> <h6 class="title">Permanent physical disability</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure permanent physical disability. </p> </section> <section id="CD002854-sec-0103"> <h6 class="title">Institutionalisation</h6> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> did not measure institutionalisation. </p> </section> </section> <section id="CD002854-sec-0104"> <h5 class="title">Other study outcomes</h5> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> also created standardised z‐scores of individual cognitive domains (memory, executive, language, visuospatial and overall cognition) and reported the change from baseline for each. There were few significant differences in cognitive function change scores between the vitamin E and placebo groups. Those that were seen (in the executive, language and overall cognitive scores) were confined to the first 18 months of the study. On average, executive function improved in both groups at six months, but the improvement was significantly greater in the vitamin E group compared to the placebo group (P &lt; 0.05). Change in language scores significantly favoured vitamin E at six months (P &lt; 0.05), 12 months (P &lt; 0.05) and 18 months (P &lt; 0.05). Overall cognitive changes scores significantly favoured vitamin E at six months (P &lt; 0.01), with an improvement in cognition in the vitamin E group and a decline in cognition in the placebo group. There were no differences between groups in the second 18 months of the study (18 to 36 months). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002854-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002854-sec-0105"></div> <section id="CD002854-sec-0106"> <h3 class="title" id="CD002854-sec-0106">Summary of main results</h3> <p>Four studies met the inclusion criteria and were selected for this review. To our knowledge there are currently no relevant ongoing trials. Three studies assessed the efficacy of vitamin E in people with AD (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>), while one study assessed vitamin E in people with MCI (<a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>). A significant limitation of this review is that synthesis of data from the AD studies was not possible owing to different outcome measures, heterogeneity in designs and the inability to access relevant data sets from authors' reports. The <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> study used a dose of vitamin E of 800 IU/day in the intervention group while the studies by <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>, <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>, and <a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> used a dose of vitamin E of 2000 IU/day. Participants in the <a href="https://archie.cochrane.org/sections/documents/view?version=z1603091745176301345482343907844%26format=REVMAN#STD-Sano-1996" target="_blank">Sano 1996</a> study withdrew from the study once they reached a series of clinical end points. We could use data only from the <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> and <a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> studies. </p> <section id="CD002854-sec-0107"> <h4 class="title">Vitamin E for dementia due to Alzheimer's disease</h4> <p>We found no evidence from the one study from which we could extract data that vitamin E was efficacious in improving cognitive outcomes in dementia due to AD (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>). We could not extract data from <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a> or <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>. </p> <p>For our other primary outcomes, adverse events and deaths, there was no evidence that participants with AD receiving vitamin E were more at risk than participants receiving placebo (<a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>; <a href="./references#CD002854-bbs2-0004" title="SanoM , ErnestoC , KlauberMR , SchaferK , WoodburyP , ThomasR , et al. and members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a‐tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders1996;10(3):132‐40. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. Effects of selegiline and alpha‐tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease. Neurology1997;48(3):A377‐8. SanoM , ErnestoC , ThomasRG , KlauberMR , SchaferK , GrundmanM , et al. for the members of the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine1997;336(17):1216‐22. SanoM , GrowdonJ , KlauberM , ErnestoC , SchaferP , WoodburyP , et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of selegiline and a‐tocopherol. Neurology1996;45 Suppl 4:289. ">Sano 1996</a>). From this review, we were unable to comment on the safety or tolerability of higher doses of alpha‐tocopherol or of other tocopherol and tocotrienol forms. In what appeared to be a post hoc analysis, <a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a> reported that the subgroup of participants with AD who responded to vitamin E with a reduction in measures of oxidative stress had similar cognitive outcomes to participants taking placebo, while participants showing no reduction in oxidative stress measures in response to vitamin E had significantly poorer cognitive outcomes. This was very low quality evidence due to the post hoc definition of response, the small sample size and other significant methodological limitations, but the apparent accelerated decline in cognitive abilities in those participants in whom vitamin E did not reduce oxidative stress measures suggests a need for caution in future trials. </p> <p>Among our secondary outcomes, we could extract data from <a href="./references#CD002854-bbs2-0001" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2014;10(1):36‐44. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer. JAMA2014;311(11):1161. DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a> on behavioural disturbance, which did not differ between groups, and on performance of activities of daily living, which declined less over a mean follow‐up of 2.27 years in the vitamin E than in the placebo group. We were unable to extract any data on our secondary outcomes of global dementia severity, mood, carer burden, quality of life, physical disability or institutionalisation. </p> </section> <section id="CD002854-sec-0108"> <h4 class="title">Vitamin E for <i>m</i>ild cognitive impairment </h4> <p><a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> was the only study identified that investigated the effects of vitamin E on the progression from MCI to AD. We found no evidence that vitamin E treatment affected the risk of progression to AD over 36 months compared to placebo. The evidence presented by <a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a> also suggests that vitamin E was not efficacious in improving cognitive outcomes in MCI. </p> <p>There was no evidence that vitamin E treatment increased the risk of death, and while we were unable to extract data for adverse events, the data presented by the authors indicated that the risk of adverse events also did not differ between treatment groups. As with the AD sample, we were unable to comment on the safety or tolerability of higher doses of alpha‐tocopherol or of other tocopherol and tocotrienol forms in an MCI population. </p> <p>Among our secondary outcomes, we were unable to analyse data on activities of daily living and global severity because sample sizes were not clearly reported. However, the data presented by the authors showed no evidence that either outcome benefited from vitamin E treatment compared to placebo. The study did not measure mood, carer burden, quality of life, physical disability or institutionalisation, so we could not draw any conclusions about the effect of vitamin E on these outcomes in an MCI population. </p> </section> </section> <section id="CD002854-sec-0109"> <h3 class="title" id="CD002854-sec-0109">Overall completeness and applicability of evidence</h3> <p>The review was based on a small number of RCTs that were heterogeneous in design thus preventing a meta‐analysis. Notably, no two studies included in this review had the same primary outcome, while only a single study investigated vitamin E treatment in a MCI population (<a href="./references#CD002854-bbs2-0003" title="PetersenR , GrundmanR , ThomasR , ThalL . Donepezil and vitamin E as treatments for mild cognitive impairment. NeuroBiology of Aging2004;25(S2):20. PetersenRC , ThomasRG , GrundmanM , BennettD , DoodyR , FerrisS , et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine2005;352(23):2379‐88. ">Petersen 2005</a>). </p> </section> <section id="CD002854-sec-0110"> <h3 class="title" id="CD002854-sec-0110">Quality of the evidence</h3> <p>Using the GRADE approach, we rated the overall quality of evidence for all outcomes to be moderate. We considered the studies from which we extracted data to be at low to unclear risk of bias. However, we downgraded all quality judgements one level due to imprecision because all data came from single modest‐sized studies and we therefore considered it likely that further research could have an impact on the effect estimates. </p> <p>See <a href="./full#CD002854-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD002854-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD002854-sec-0111"> <h3 class="title" id="CD002854-sec-0111">Potential biases in the review process</h3> <p>To minimise the possibility of bias, we tried to locate all RCTs by a broad and comprehensive search strategy in a number of databases. We sought additional information from the authors of one study but were unable to obtain it (<a href="./references#CD002854-bbs2-0002" title="LloretA , BadíaMC , MoraNJ , PallardóFV , AlonsoMD , ViñaJ . Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease2009;17(1):143‐9. ">Lloret 2009</a>). The review was limited by our inability to obtain or extract the data we needed from two of the included studies. </p> </section> <section id="CD002854-sec-0112"> <h3 class="title" id="CD002854-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>Habitual intake of dietary antioxidants has not consistently been found to improve cognitive performance or reduce the risk of dementia (<a href="./references#CD002854-bbs2-0094" title="CrichtonGE , BryanJ , Murphy , KJ . Dietary antioxidants, cognitive function and dementia ‐ a systematic review. Plant Foods for Human Nutrition2013;68:279‐92. ">Crichton 2013</a>). While vitamin E assessed in epidemiological studies in relation to cognition has consisted of the various naturally occurring forms (<a href="./references#CD002854-bbs2-0097" title="EngelhartMJ , GeerlingsMI , RuitenbergA , vanSwietenJC , HofmanA , WittemanJC , et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA2002;287(24):3223‐9. ">Engelhart 2002</a>; <a href="./references#CD002854-bbs2-0120" title="MorrisMC , EvansDA , BieniasJL , TangneyCC , BennettDA , AggarwalN , et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA2002;287(24):3230‐7. ">Morris 2002</a>; <a href="./references#CD002854-bbs2-0121" title="MorrisMC , EvansDA , TangneyCC , BieniasJL , WilsonRS , AggarwalNT , et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. American Journal of Clinical Nutrition2005;81(2):508‐14. ">Morris 2005</a>), the relationship between vitamin E and cognition is unclear. In the present systematic review, there was no evidence that vitamin E improved either cognition or risk of developing AD. <a href="./references#CD002854-bbs2-0121" title="MorrisMC , EvansDA , TangneyCC , BieniasJL , WilsonRS , AggarwalNT , et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. American Journal of Clinical Nutrition2005;81(2):508‐14. ">Morris 2005</a> suggested that the combined intake of tocopherols is likely to be more important than alpha‐tocopherol alone. This is further supported by <a href="./references#CD002854-bbs2-0113" title="MangialascheF , KivipeltoM , MecocciP , RizzutoD , PalmerK , WinbladB , et al. High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. Journal of Alzheimer's Disease2010;20(4):1029‐37. ">Mangialasche 2010</a> who studied the relationship between cognitive impairment and the eight individual forms of vitamin E and concluded that any potential neuroprotective effect for vitamin E may result from interaction of the various forms. </p> <p>It has been previously reported that vitamin E, especially in the large doses used in the included studies, may be associated with potentially significant adverse effects and even an increased rate of all‐cause mortality (<a href="./references#CD002854-bbs2-0119" title="MillerER , Pastor‐BarriusoR , DalalD , RiemersmaRA , AppelLJ , GuallarE . Meta‐analysis: high‐dosage vitamin E supplementation may increase all‐cause mortality. Annals of Internal Medicine2005;142:37‐46. ">Miller 2005</a>). High doses of alpha‐tocopherol also have the potential to induce enzymes involved in drug metabolism with an associated risk of serious interactions with some concomitant medication (<a href="./references#CD002854-bbs2-0089" title="Brigelius‐FlohéR . Adverse effects of vitamin E by induction of drug metabolism. Genes &amp; Nutrition2007;2(3):249‐56. ">Brigelius‐Flohé 2007</a>). However, this review found no evidence that vitamin E treatment significantly affected the number of serious adverse events or deaths, although the relatively short study lengths and small sample sizes mean that no strong conclusions about the safety of vitamin E can be drawn from these data. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002854-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for study for the search April 2016." data-id="CD002854-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for study for the search April 2016.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002854-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002854-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 1 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) (least square (LS) mean change from baseline at 6 to 48 months): completers." data-id="CD002854-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 1 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) (least square (LS) mean change from baseline at 6 to 48 months): completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 2 Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS‐ADL) (LS mean change from baseline at 6 to 48 months): completers." data-id="CD002854-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 2 Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS‐ADL) (LS mean change from baseline at 6 to 48 months): completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 3 Deaths (number of deaths over 48 months)." data-id="CD002854-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 3 Deaths (number of deaths over 48 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 4 Serious adverse events (number of participants reporting ≥ 1 serious adverse event over 48 months)." data-id="CD002854-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 4 Serious adverse events (number of participants reporting ≥ 1 serious adverse event over 48 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to 48 months): completers." data-id="CD002854-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to 48 months): completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 6 Mini‐Mental State Examination (MMSE) (LS mean change from baseline at 6 to 48 months): completers." data-id="CD002854-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 6 Mini‐Mental State Examination (MMSE) (LS mean change from baseline at 6 to 48 months): completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 7 Adverse events (number of participants reporting ≥ 1 adverse event over 48 months)." data-id="CD002854-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease, Outcome 7 Adverse events (number of participants reporting ≥ 1 adverse event over 48 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment, Outcome 1 Progression to Alzheimer's disease (AD) (number of people progressing to AD by 36 months)." data-id="CD002854-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment, Outcome 1 Progression to Alzheimer's disease (AD) (number of people progressing to AD by 36 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002854-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/urn:x-wiley:14651858:media:CD002854:CD002854-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_t/tCD002854-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment, Outcome 2 Deaths (number of deaths over 36 months)." data-id="CD002854-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment, Outcome 2 Deaths (number of deaths over 36 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/media/CDSR/CD002854/image_n/nCD002854-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002854-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> multicentre, US </p> <p><b>Intervention:</b> vitamin E (capsules 2000 IU/day in 2 divided doses) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin E (capsules 2000 IU/day in 2 divided doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> <br/> LS mean change from baseline using the ADAS‐Cog </p> <p>Scale from: 0 to 70</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in cognitive function in placebo group was <b>7.78</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in cognitive function in the intervention group was <b>1.81 lower</b> <br/> (3.75 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores represent worse cognitive function.</p> <p>A 4‐point difference in ADAS‐cog has been considered the MCID.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Number of participants reporting ≥ 1 serious adverse event</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> <br/> (444 to 656) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.71 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> <p>Number of deaths</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (106 to 273) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/> (0.52 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> <br/> LS mean change from baseline using the ADCS‐ADL </p> <p>Scale from: 0 to 78</p> <p>Follow‐up: 6 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in activities of daily living in the placebo group was <b>‐16.96</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The LS mean change from baseline in activities of daily living in the intervention group was <b>3.15 higher</b> <br/> (0.07 to 6.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores represent better activities of daily living.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer Disease Assessment Scale ‐ Cognitive Subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory;<b>CI:</b> confidence interval; <b>LS:</b> least square; <b>MCID:</b> minimum clinically important difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due to imprecision. Evidence from a single study of modest size. This is supported by dichotomous data not reaching the optimal information size criterion (assuming α of 0.05, and β of 0.2) (<a href="./references#CD002854-bbs2-0102" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002854-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with mild cognitive impairment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with mild cognitive impairment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild cognitive impairment<br/> <b>Settings:</b> US and Canada<br/> <b>Intervention:</b> vitamin E (capsules 2000 IU/day in 2 divided doses)<br/> <b>Comparison:</b> placeb </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin E (capsules 2000 IU/day in 2 divided doses) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to Alzheimer's disease</b> </p> <p>Number of people progressing to AD</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> <br/> (224 to 383) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.79 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> <p>Mean change from baseline of ADAS‐Cog</p> <p>Scale from: 0 to 70</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncertainty about how missing data were handled. Study reports no significant difference between intervention and control groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Number of participants reporting ≥ 1 serious adverse event.</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>516<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse event rates not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Number of deaths over 36 months</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (6 to 66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.3 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Activities of daily living</b> </p> <p>Mean change from baseline using the ADCS<br/> Mild Cognitive Impairment Activities of Daily Living </p> <p>Scale from: 0 to 53</p> <p>Follow‐up: 36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not possible to extract data for analysis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to evaluate quality of evidence.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncertainty about how missing data were handled. Study reports no significant difference between intervention and control groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer Disease Assessment Scale ‐ Cognitive Subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory;<b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due to imprecision. Evidence from a single study of modest size. This was supported by dichotomous data not reaching the optimal information size criterion (assuming α of 0.05, and β of 0.2) (<a href="./references#CD002854-bbs2-0102" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) compared to placebo for people with mild cognitive impairment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/full#CD002854-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002854-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) (least square (LS) mean change from baseline at 6 to 48 months): completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.81 [‐3.75, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS‐ADL) (LS mean change from baseline at 6 to 48 months): completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.07, 6.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deaths (number of deaths over 48 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.52, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (number of participants reporting ≥ 1 serious adverse event over 48 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.71, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to 48 months): completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐4.26, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mini‐Mental State Examination (MMSE) (LS mean change from baseline at 6 to 48 months): completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.72, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events (number of participants reporting ≥ 1 adverse event over 48 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002854-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression to Alzheimer's disease (AD) (number of people progressing to AD by 36 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Deaths (number of deaths over 36 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.30, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002854.pub5/references#CD002854-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002854.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002854-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002854-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002854-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002854-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002854-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002854-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002854-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002854-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD002854-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002854-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002854\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002854\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002854\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002854\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002854\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002854.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002854.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002854.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002854.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002854.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728013280"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002854.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728013283"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002854.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eba187d34937f',t:'MTc0MDcyODAxMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 